Skip to content

THE ROLE OF LIFE STYLE AND DIET MODIFICATIONS ON TREATMENT OF CHRONIC PELVIC PAIN SYNDROME

THE ROLE OF LIFE STYLE AND DIET MODIFICATIONS ON TREATMENT OF CHRONIC PELVIC PAIN SYNDROME - THE ROLE OF LIFE STYLE AND DIET MODIFICATIONS ON TREATMENT OF CHRONIC PELVIC PAIN SYNDROME

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000005456
Enrollment
100
Registered
2011-04-18
Start date
2011-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pelvic pain syndrome (CPPS)

Interventions

- Nimesulide 100 mg bidaly for a week - Serenoa repens (Saw Palmetto) 320 mg one tablet each day for three months - Modification of diet and life-style change - Nimesulide 100 mg bidaly for a we

Sponsors

Studio Urologico Gallo
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1) patients coming to our center with a diagnosis of Category IIIa or IIIb CPPS (with or without presence of leukocytes) 2) age between 20 and 50 years 3) a score of > 1 in pain domain of NIH-CPSI 4) duration of symptoms for more than 3 months 5) presence at clinical history of at least one lifestyle or diet risk factors.

Exclusion criteria

Exclusion criteria: 1) diagnosis of a bacterial form of prostatitis (category I and II of NIH) assessed after lower urinary tract localisation studies 2) a previous urinary tract infection within the last year 3) assumption of drugs which could modify lower urinary tract function during the previous three months 4) Severe gastric problems , coagulation problems, renal and/or epatic failure contraindicating assumption of NSAIDs.

Design outcomes

Primary

MeasureTime frame
The change in the mean total NIH Chronic Prostatitis Symptom Index (NIH-CPSI) scores of the two groups from baseline to after three months of treatment.

Secondary

MeasureTime frame
The change in mean NIH- CPSI subdomains (pain, micturition, QoL) of the two groups pre- and aftertreatment.

Countries

Europe

Contacts

Public ContactLuigi Gallo

Studio Urologico Gallo Urology

info@studiourologicogallo.it+390817649530

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026